RecruitingPhase 3NCT05342792

Metronomic Capecitabine With or Without PD-1 Antibody as Adjuvant Therapy in High-risk Nasopharyngeal Carcinoma

Studying Nasopharyngeal carcinoma

Last synced from ClinicalTrials.gov

ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Sun Yat-sen University
Principal Investigator
Jun Ma, MD
Sun Yet-senU
Intervention
PD-1 antibody(drug)
Enrollment
556 target
Eligibility
18-65 years · All sexes
Timeline
2022 – 2029

Study locations (1)

Collaborators

Tongji Hospital · Union Hospital, Tongji Medical College, Huazhong University of Science and Technology · Xiangya Hospital of Central South University · Affiliated Cancer Hospital of Guizhou Medical University · Cancer Hospital of Guangxi Medical University · First People's Hospital of Foshan · Chongqing University Cancer Hospital · Hubei Cancer Hospital · Hunan Cancer Hospital · The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School · Fifth Affiliated Hospital, Sun Yat-Sen University · Shandong Provincial Hospital

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT05342792 on ClinicalTrials.gov

Other trials for Nasopharyngeal carcinoma

Additional recruiting or active studies for the same condition.

See all trials for Nasopharyngeal carcinoma →

← Back to all trials